-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For patients with atrial fibrillation (AF) who are at high risk of stroke, all major guidelines recommend oral anticoagulant therapy.
Recently, Professor A John Camm, a clinical and academic group of cardiology at St.
The GARFIELD-AF study is a prospective, multinational, observational study that included 25,551 adults who were recently diagnosed with non-valvular atrial fibrillation and had at least one risk factor for stroke.
Among them, 8605 patients (median age 73 years old, 52% males) were treated with VKAs, 2090 patients (median age 72 years old, 55% males) were treated with DTI, and 7694 patients (median age 75 years old, 53% males) ) Using factor Xa inhibitors, 7162 patients (median age 73 years, 54% male) did not receive any oral anticoagulant therapy.
The results showed that compared with patients who were not treated with oral anticoagulants, the use of any oral anticoagulant can reduce mortality (HR=0.
However, compared with patients without oral anticoagulation therapy, NOACs treatment reduced mortality (HR=0.
Compared with VKAs, NOACs treatment can reduce all-cause mortality (3.
In the vast majority of patients with atrial fibrillation, international guidelines recommend that NOACs are widely superior to VKAs, because clinical trials have always shown the non-inferiority and better safety of NOACs, and reduce the risk of intracranial hemorrhage.
Original source:
A John Camm, Keith AA Fox, Saverio Virdone, et al.
bmj.
com/content/early/2021/02/15/heartjnl-2020-318420" target="_blank" rel="noopener">Comparative effectiveness of oral anticoagulants in everyday practice.
Leave a message here
